Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

88.91USD
20 Jul 2018
Change (% chg)

$-1.04 (-1.16%)
Prev Close
$89.95
Open
$88.71
Day's High
$89.63
Day's Low
$86.76
Volume
2,153,801
Avg. Vol
1,986,526
52-wk High
$125.84
52-wk Low
$69.40

Select another date:

Tue, Jul 17 2018

Photo

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

Mylan signs U.S. license deal on Humira with AbbVie

July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

AbbVie wins reversal of $140 million verdict in case over AndroGel risks

A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.

UPDATE 2-AbbVie wins reversal of $140 mln verdict in case over AndroGel risks

July 5 A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.

U.S. judge tosses $140 mln verdict against AbbVie in AndroGel case

July 5 A U.S. judge on Thursday overturned a $140 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.

AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge

A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

UPDATE 2-AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge

June 29 A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

CORRECTED-UPDATE 1-AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge

June 29 A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

CORRECTED-Abbvie, Androgel partner owe $448 million in antitrust case -U.S. judge

June 29 A U.S. judge on Friday found that Abbvie Inc used sham litigation to illegally prevent generic versions of testosterone gel AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

Select another date: